At a workshop on managing conflicts of interest in medicine, Chris Winchester, CEO of Oxford PharmaGenesis and co-founder of Open Pharma, argued for openness.
On 11–12 June 2019, over 60 pharma stakeholders met in Amsterdam at the 8th Annual Publication and Clinical Trial Transparency Conference to discuss the evolving landscape of clinical trial transparency.
On 15 May 2019, the Center for Biomedical Research Transparency (CBMRT) brought the stakeholders in academic publishing together to share their varying perspectives on research transparency and accessibility at the European Biomedical Transparency Summit (BMTS), in Paris.
Featuring pharma taking the lead on sharing clinical trial results, where preprints end up, and the identity of peer reviewers.
In order to protect the quality of clinical research it is vital for all trials to be represented in scientific literature for the benefit of scientific progress and research efficiency, and, ultimately, to better inform care for our patients in a timely manner.
Here’s our summary of key points from selected presentations at the 2018 European meeting of ISMPP.
Based on our experience, we believe that ORCID can make medical publishing faster and more transparent.
With CRediT, ORCID and Publons integrated into Editorial Manager®, we aim for these transparency tools to be easy, standard steps in the publishing process
Personal commentary from Richard Smith, chair of Open Pharma
Since the sudden disappearance of his list of so-called predatory journals in January 2017, Jeffrey Beall has maintained silence on the subject for which he has become famous. In a recent webinar, a recording of which can be accessed here, this silence was broken. His emergence back into the public eye is part of a … Continue reading Predatory journals are back in the firing line